ArticleResearch and practice in thrombosis and haemostasis2025
Haemophilia B: an illustrative review of current challenges and opportunities.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Personalized Treatment of Hemophilia: Matching Therapies to Patient Needs in a Rapidly Evolving Landscape.Drugs · 2026Review
- Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization.Pharmaceutics · 2026Article
- Haemorrhagic Cholecystitis: A Rare Form of Haemorrhagic Shock in a Patient With a Double Risk.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. Advances in therapeutic strategies for hemophilia B have significantly improved patient outcomes but have also necessitated ongoing education for healthcare professionals. This illustrated review provides an overview of the challenges and opportunities in hemophilia B care, including best practice management, emerging therapies, and remaining research needs. Objectives: To provide a comprehensive visual summary of contemporary perspectives on hemophilia B pathophysiology and management through an illustrated review. Methods: The authors, leveraging their clinical experience and expertise in hemophilia B management, conducted a review of relevant articles in PubMed (Supplementary Methods). Results: The review is divided into illustrated sections that provide an overview of hemophilia B, detailing its clinical manifestations, hemostatic agents, and treatment challenges. It also examines the pharmacokinetic properties of hemophilia B and the importance of individualized treatment approaches. Conclusion: This illustrated review educates healthcare professionals on hemophilia B management in the current treatment landscape, empowering them to further disseminate knowledge to both their colleagues and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.